Division of Ethics, Department of Medical Humanities and Ethics, Columbia University, New York, New York, USA.
Department of Social and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.
AJOB Empir Bioeth. 2024 Apr-Jun;15(2):108-119. doi: 10.1080/23294515.2023.2279965. Epub 2023 Nov 14.
Over the last decade, the return of results (ROR) in precision medicine research (PMR) has become increasingly routine. Calls for individual rights to research results have extended the "duty to report" from clinically useful genetic information to traits and ancestry results. ROR has thus been reframed as inherently beneficial to research participants, without a needed focus on who benefits and how. This paper addresses this gap, particularly in the context of PMR aimed at increasing participant diversity, by providing investigator and researcher perspectives on and questions about the assumed value of ROR in PMR.
Semi-structured interviews with a purposive sample of investigators and researchers across federally funded PMR studies in three national consortia, as well as observations of study activities, focused on how PM researchers conceptualize diversity and implement inclusive practices across research stages, including navigating ROR.
Interviewees (1) validated the value of ROR as a benefit of PMR, while others (2) questioned the benefit of clinically actionable results to individuals in the absence of sufficient resources for translating findings into health care for diverse and disadvantaged populations; (3) expressed uncertainties in applying the presumed value of ROR as a benefit for clinical results; and (4) and debated when the promise of the value of ROR may undermine trust in PMR, and divert efforts to return value beyond ROR.
Conceptualizations of diversity and inclusion among PM researchers and investigators raise unique ethical questions where unexamined assumptions of the value of ROR inform study recruitment efforts to enroll minoritized and under-represented populations. A lack of consideration for resources and infrastructure necessary to translate ROR into actionable information may hinder trustworthy community-research relationships. Thus, we argue for a more intentional interrogation of ROR practices as an offer of benefit and for whom.
在过去的十年中,精准医学研究(PMR)的结果回报(ROR)变得越来越普遍。对研究结果的个人权利的呼吁,已经将“报告义务”从具有临床意义的遗传信息扩展到特征和祖先结果。因此,ROR 被重新定义为对研究参与者本身有益,而无需关注谁受益以及如何受益。本文通过提供调查人员和研究人员对 PMR 中 ROR 假设价值的看法和问题,特别是在旨在增加参与者多样性的 PMR 背景下,解决了这一差距。
对三个国家联盟中联邦资助的 PMR 研究中具有特定目的的调查人员和研究人员进行半结构式访谈,并观察研究活动,重点关注 PM 研究人员如何概念化多样性,并在研究阶段实施包容性实践,包括ROR。
受访者(1)验证了 ROR 作为 PMR 的一种益处的价值,而其他人(2)质疑在缺乏将研究结果转化为多样化和弱势群体的医疗保健的足够资源的情况下,临床可操作结果对个人的益处;(3)对将 ROR 的假定价值应用为临床结果的益处表示不确定;(4)并就 ROR 的价值承诺何时可能破坏对 PMR 的信任,并转移努力以超越 ROR 回报价值进行了辩论。
PM 研究人员和调查人员对多样性和包容性的概念化提出了独特的伦理问题,在这些问题中,ROR 价值的未经检验的假设会影响研究招募工作,以招募少数族裔和代表性不足的人群。缺乏考虑将 ROR 转化为可操作信息所需的资源和基础设施,可能会阻碍值得信赖的社区研究关系。因此,我们主张更有意地询问 ROR 实践作为提供利益的一种方式,以及为谁提供利益。